Skip to content

Comparison of Pulmonary Functions and Respiratory Muscle Strength Between Children With Hearing Impairment and Healthy Peers

Comparison of Pulmonary Functions and Respiratory Muscle Strength Between Children With Hearing Impairment and Healthy Peers

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07421349
Enrollment
30
Registered
2026-02-19
Start date
2026-02-20
Completion date
2026-06-30
Last updated
2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Children, Hearing Loss, Bilateral Sensorineural, Pulmonary Function, Respiratory Muscle Strength

Brief summary

This study aims to compare pulmonary function and respiratory muscle strength between children with hearing impairment and their healthy peers. Hearing plays a critical role not only in communication but also in cognitive, sensory, and psychomotor development. Children with hearing impairment may experience balance and coordination problems, vestibular dysfunction, and reduced muscle strength, which may negatively affect respiratory function. Although several studies have evaluated pulmonary function in children with hearing impairment, research investigating respiratory muscle strength in this population is limited. To our knowledge, no peer-reviewed study has directly compared respiratory muscle strength between children with hearing impairment and healthy controls. This study will compare spirometric parameters and respiratory muscle strength measurements between children with hearing impairment and age-matched healthy controls.

Interventions

None listed

Sponsors

Bezmialem Vakif University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
7 Years to 16 Years
Healthy volunteers
Yes

Inclusion criteria

For Children With Hearing Loss Group: * Aged between 7 and 16 years * Diagnosed with hearing loss * No neurological or orthopedic disorders * No syndrome and/or disease causing intellectual disability, developmental disorder, or visual impairment * No use of medication affecting respiratory function within the last 3 months * Written informed consent obtained from parent or legal guardian For Healthy Control Group: * Aged between 7 and 16 years * No hearing impairment * No neurological or orthopedic disorders * No syndrome and/or disease causing intellectual disability, developmental disorder, or visual impairment * No use of medication affecting respiratory function within the last 3 months * Written informed consent obtained from parent or legal guardian

Exclusion criteria

(Both Groups) * Intellectual disability preventing participation in assessment procedures * Presence of chronic respiratory disease * Inability to perform pulmonary function or respiratory muscle strength tests properly

Design outcomes

Primary

MeasureTime frameDescription
Maximum Inspiratory Pressure (MIP)At baseline (single assessment)Respiratory muscle strength assessed by measuring maximum inspiratory pressure (cmH₂O) using a portable electronic mouth pressure device (MicroRPM) according to ATS/ERS guidelines.
Maximum Expiratory Pressure (MEP)At baseline (single assessment)Forced vital capacity measured by spirometry (COSMED Pony FX) according to ATS/ERS criteria; values expressed as absolute and percentage of predicted values.

Secondary

MeasureTime frameDescription
Forced Vital Capacity (FVC)At baseline (single assessment)Forced vital capacity measured by spirometry (COSMED Pony FX) according to ATS/ERS criteria; values expressed as absolute and percentage of predicted values.
Forced Expiratory Volume in 1 Second (FEV1)At baseline (single assessment)Forced expiratory volume in the first second measured by spirometry; values expressed as absolute and percentage of predicted values.
FEV1/FVC RatioAt baseline (single assessment)Ratio of FEV1 to FVC obtained from spirometric assessment.
Peak Expiratory Flow (PEF)At baseline (single assessment)Peak expiratory flow measured by spirometry.
Forced Expiratory Flow 25-75% (FEF25-75%)At baseline (single assessment)Forced expiratory flow between 25% and 75% of FVC measured by spirometry.

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 14, 2026